Located in Charlotte, NC, The Neurological Institute works to increase our understanding of neurological diseases while improving treatment modalities through a range of medical studies. The Neurological Institute also provides a number of treatment options for people in and around Charlotte, NC, who have neurological conditions, such as Parkinson’s disease. This disease affects the basal ganglia and leads to a deficiency in the neurotransmitter dopamine.
The US Food and Drug Administration recently made history by approving amantadine extended-release capsules for treatment in patients with Parkinson’s who receive levodopa-based therapy. This new drug treats dyskinesia, the involuntary movements that result from the disease. Amantadine is the first drug proven to reduce dyskinesia in controlled trials.
JAMA Neurology published the results of a phase 3 placebo-controlled trial of the drug. In the study, patients took the drug at night, so that plasma concentration would peak by morning and be sustained throughout the day. Trials found that the drug results in a statistically significant decrease in dyskinesia when compared to a placebo. Patients tended to increase their daily functional time by three and a half to four hours.
No comments:
Post a Comment